Format

Send to

Choose Destination
Oncotarget. 2016 Aug 30;7(35):56998-57010. doi: 10.18632/oncotarget.10933.

A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?

Author information

1
Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, HB, China.
2
Department of Oncology, Shenzhen People Hospital, Shenzhen, China.
3
Department of Radiology, Hubei Cancer Hospital, Wuhan, HB, China.
4
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.

Abstract

Lung adenocarcinomas are more commonly associated with brain metastases (BM). Epidermal growth factor receptor (EGFR) mutations have been demonstrated to be both predictive and prognostic for patients with lung adenocarcinoma. We aimed to explore the potential association between EGFR mutation and the risk of BM in pulmonary adenocarcinoma patients. Data of 234 patients from 2007 to 2014 were retrospectively reviewed. A total of 108 patients had EGFR mutations in the entire cohort. Among them, 76 patients developed BM during their disease course. The incidence of BM was statistically higher in patients with EGFR mutations both at initial diagnosis (P=0.014) and at last follow-up (P<0.001). Multivariate logistic regression analysis revealed that EGFR mutation significantly increased the risk of BM at initial diagnosis (OR=2.515, P=0.022). In patients without BM at initial diagnosis, the accumulative rate of subsequent BM was significantly higher with EGFR mutations (P=0.001). Multivariate Cox regression analysis identified EGFR mutation as the only independent risk factor for subsequent BM (HR=3.036, P=0.001). Patients with EGFR mutations demonstrated longer overall survival (OS) after BM diagnosis than patients with wild-type EGFR (P=0.028). Our data suggest that EGFR mutation is an independent predictive and prognostic risk factor for BM and a positive predictive factor for OS in patients with BM.

KEYWORDS:

EGFR; brain metastasis; lung adenocarcinoma; mutation; retrospective study

PMID:
27486770
PMCID:
PMC5302968
DOI:
10.18632/oncotarget.10933
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center